Australia's most trusted
source of pharma news
Posted 9 December 2021 AM
Roche's targeted oncology drug Gavreto has made its first regulatory appearance in Australia with the TGA offering the company the provisional approval pathway for three potential indications.
The Swiss pharma giant inked a deal worth up to US$1.7 billion (AUD $2.38 billion) with drugs developer Blueprint Medicines in mid-2020, taking a bet to commercialise the drug, previously known as pralsetinib, in countries outside the US.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.